Electrolytic ablation as an adjunct to liver resection: Safety and efficacy in patients
Electrolytic ablation as an adjunct to liver resection: Safety and efficacy in patients
复制标题
DOI：
10.1046/j.1445-2197.2002.02471.x
复制
发表时间：
2002-08-01
影响因子：
1.7
通讯作者：
Maddern, GJ
中科院分区：
文献类型：
--
作者：
Wemyss-Holden, SA;Berry, DP;Maddern, GJ
背景：电解消融是一种相对较新的局部破坏结直肠肝转移瘤的方法。动物模型的实验工作表明，这种方法是安全和有效的。然而，在进行临床试验之前，有必要确认这些发现在一个试点研究的5 patients.Methods：5例结直肠癌肝转移进行了前瞻性研究。每例患者均接受了潜在治愈性肝切除术。其中一个待切除的转移瘤在切除前使用电解治疗。在电解期间和电解后密切监测每例患者，以确定与治疗相关的任何发病率。一旦切除，转移组织学检查的完整性ablation.Results：所有患者耐受电解良好，有没有死亡或并发症相关的治疗。切除的转移瘤，已被电解治疗的组织学检查显示完全的组织破坏，没有活的恶性细胞剩余在site of treatment.Discussion：电解消融肝转移瘤在5例患者中的试验研究显示，治疗是耐受性良好，安全。此外，它证明了电解部位的恶性组织的完全破坏。基于这些令人鼓舞的结果，临床试验现在可以开始了。
Background: Electrolytic ablation is a relatively new method for the local destruction of colorectal liver metastases. Experimental work in animal models has shown this method to be safe and efficacious. However, before proceeding to clinical trials it was necessary to confirm these findings in a pilot study of five patients.Methods: Five patients with colorectal liver metastases were studied prospectively. Each patient underwent a potentially curative liver resection. One of the metastases to be removed was treated using electrolysis before resection. Each patient was monitored closely during and after electrolysis to determine any morbidity associated with the treatment. Once resected, the metastases were examined histologically for completeness of ablation.Results: All patients tolerated the electrolysis well; there were no deaths or complications related to the treatment. Histological examination of the resected metastases which had been treated electrolytically showed complete tissue destruction with no viable malignant cells remaining at the site of treatment.Discussion: This pilot study of electrolytic ablation of liver metastases in five patients showed the treatment to be well tolerated and safe. Additionally, it demonstrated total destruction of the malignant tissue at the site of electrolysis.Based on these encouraging results, clinical trials can now begin.